2. Search Result
Search Result
Results for "

human immunodeficiency virus type-1 (HIV-1)

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

3

Peptides

1

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-111964
    Lenacapavir
    15+ Cited Publications

    GS-6207

    		 HIV Infection
    Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
    Lenacapavir
  • HY-169848
    (S)-Batylalcohol

    1-O-Octadecyl-sn-glycerol

    		 HIV Infection
    (S)-Batylalcohol (1-O-Octadecyl-sn-glycerol) is a phosphonoformic acid (PFA) analog that exhibits higher in vitro antiviral activity against human immunodeficiency virus type 1 (HIV-1) than PFA. (S)-Batylalcohol can be used in antiretroviral research .
    (S)-Batylalcohol
  • HY-111964A
    Lenacapavir sodium
    15+ Cited Publications

    GS-6207 sodium

    		 HIV Infection
    Lenacapavir (GS-6207) sodium is an HIV-1 capsid inhibitor. Lenacapavir sodium binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir sodium exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir sodium is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
    Lenacapavir sodium
  • HY-102026
    Formycin A

    NSC 102811

    		 HIV Nucleoside Antimetabolite/Analog Antibiotic Infection Cancer
    Formycin A (NSC 102811), a purine nucleoside antibiotic, is a potent human immunodeficiency virus type 1 (HIV-1) inhibitor with an EC50 of 10 μM. Formycin A shows antitumor and antiviral activities .
    Formycin A
  • HY-106958
    Talviraline

    HBY 097

    		 HIV Reverse Transcriptase Infection
    Talviraline is a non-nucleoside reverse transcriptase (NNRT) inhibitor that is primarily used to inhibit the replication of human immunodeficiency virus type 1 (HIV-1). Talviraline inhibits the viral replication process by binding to a specific site of HIV-1 reverse transcriptase (RT). Talviraline can be used to study the potential countermeasures and safety of HIV-1 infection .
    Talviraline
  • HY-14891
    Fosdevirine

    GSK2248761; FDV

    		 HIV Reverse Transcriptase Infection
    Fosdevirine (GSK2248761) is is a potent, selective, non-nucleoside reverse transcriptase inhibitor (NNRTI) of human immunodeficiency virus type 1 (HIV-1) replication with low nanomolar activity in vitro. Fosdevirine shows good activity against a broad range of HIV-1 strains, including efavirenz (HY-10572)-resistant clinical isolates .
    Fosdevirine
  • HY-P35433
    Tifuvirtide

    T-1249

    		 HIV Inflammation/Immunology
    Tifuvirtide (T-1249) is a peptide human immunodeficiency virus type-1 (HIV-1) fusion inhibitor. Tifuvirtide is a synthetically designed hybrid retroviral envelope polypeptide. Tifuvirtide has antiretroviral activity. Tifuvirtide can be used for the research of HIV infection .
    Tifuvirtide
  • HY-106395
    Telinavir

    SC-52151

    		 HIV Protease HIV Infection
    Telinavir (SC-52151) is a potent and selective HIV protease inhibitor. Telinavir inhibits lymphotropic, monocytotropic strains and field isolates of HIV type 1 (HIV-1), HIV-2, and simian immunodeficiency virus with EC50s of 26 ng/mL (43 nM). Telinavir is highly protein bound in human plasma and exhibits low partitioning into erythrocytes .
    Telinavir
  • HY-N1034
    12-Oxocalanolide A

    (±)-12-Oxocalanolide A

    		 HIV Infection
    12-Oxocalanolide A (compound 6) is a potent inhibitor of reverse transcriptase from human immunodeficiency virus type 1 (HIV-1) with an IC50 and EC50 of 2.8 and 12 μM, respectively. 12-Oxocalanolide A is the analogue of Calanolide .
    12-Oxocalanolide A
  • HY-106395A
    (Rac)-Telinavir

    (Rac)-SC-52151

    		 HIV Protease HIV Infection
    (Rac)-Telinavir ((Rac)-SC-52151) is a racemate of Telinavir (HY-106395A). Telinavir (SC-52151) is a potent and selective HIV protease inhibitor. Telinavir inhibits lymphotropic, monocytotropic strains and field isolates of HIV type 1 (HIV-1), HIV-2, and simian immunodeficiency virus with EC50s of 26 ng/mL (43 nM). Telinavir is highly protein bound in human plasma and exhibits low partitioning into erythrocytes .
    (Rac)-Telinavir
  • HY-19194
    A-80987

    		HIV Protease Infection
    A-80987 is an inhibitor of human immunodeficiency virus type 1 (HIV-1) protease .
    A-80987
  • HY-14135
    BMS 488043

    BMS 043

    		 HIV Infection Inflammation/Immunology
    BMS 488043 (BMS 043) is an orally active and well-tolerated inhibitor of the attachment of human immunodeficiency virus type 1 (HIV-1) to CD4+ lymphocytes .
    BMS 488043
  • HY-P1753
    VIR-165

    		HIV Infection
    VIR-165 is a modified form of virus inhibitory peptide (VIRIP) that binds the fusion peptide of the gp41 subunit and prevents its insertion into the target membrane. VIRIP inhibits a wide variety of human immunodeficiency virus type 1 (HIV-1) strains .
    VIR-165
  • HY-16907
    GSK-364735

    S/GSK-364735

    		 HIV HIV Integrase Infection
    GSK-364735 is a potent antiretroviral agent against human immunodeficiency virus type 1 (HIV-1) and serves as an integrase inhibitor with an IC50 of 8 ± 2 nM. GSK-364735 can be utilized in antiviral research .
    GSK-364735
  • HY-139794
    SDZ283-910

    		HIV Infection
    SDZ283-910 is a potent human immunodeficiency virus type-1 (HIV-1) protease inhibitor .
    SDZ283-910
  • HY-15353
    Emivirine

    MKC-442

    		 HIV Infection Inflammation/Immunology
    Emivirine (MKC-442) is a non-nucleoside reverse transcriptase inhibitors (NNRTIs) with Ki values of 0.20 and 0.01 μM for dTTP- and dGTP-dependent DNA or RNA polymerase activity, respectively. Emivirine displays potent and selective anti-human immunodeficiency virus type 1 (HIV-1) activity .
    Emivirine
  • HY-B0155
    Vicriviroc

    SCH 417690; SCH-D; MK-7690 free base

    		 CCR HIV Infection Cancer
    Vicriviroc (SCH 417690) is an orally active CCR5 antagonist with the IC50 of 10 nM, and also inhibts MIP-1α and intracellular calcium release induced by the ligand RANTES (10 nM) with the IC50 values of 0.91 nM and 16 nM,,respectively. Vicriviroc can inhibits human immunodeficiency virus type 1 (HIV-1) infection, and can also used for study of cancer .
    Vicriviroc
  • HY-125433
    A-75925

    		HIV Infection
    A-75925 is a human immunodeficiency virus type 1 (HIV-1) proteinase inhibitor and can be utilized in HIV-1 rersearch .
    A-75925
  • HY-105386
    HI-280

    		HIV Reverse Transcriptase Infection
    HI-280 is a human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitor. HI-280 can be used for the research of infection .
    HI-280
  • HY-122453
    Palinavir

    		HIV Protease Infection
    Palinavir is a potent human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) protease inhibitor with an IC50 of 0.5-30 nM . Palinavir has antiviral activity .
    Palinavir
  • HY-118740
    L-708906

    		HIV Infection
    L-708906 is a potent human immunodeficiency virus type 1 (HIV-1) inhibitor with an IC50 value of 12 μM. L-708906 inhibits HIV strains resistant to nonnucleoside or nucleoside reverse transcriptase inhibitors .
    L-708906
  • HY-16907A
    GSK-364735 potassium

    S/GSK-364735 potassium

    		 HIV HIV Integrase Infection
    GSK-364735 potassium (S/GSK-364735 potassium) is the potassium salt form of GSK-364735 (HY-16907). GSK-364735 potassium is an antiretroviral, that inhibits the integrase of human immunodeficiency virus type 1 (HIV-1) with an IC50 of 7.8 nM .
    GSK-364735 potassium
  • HY-16907B
    GSK-364735 sodium

    S/GSK-364735 sodium

    		 HIV HIV Integrase Infection
    GSK-364735 sodium (S/GSK-364735 sodium) is the sodium salt form of GSK-364735 (HY-16907). GSK-364735 sodium is an antiretroviral, that inhibits the integrase of human immunodeficiency virus type 1 (HIV-1) with an IC50 of 7.8 nM .
    GSK-364735 sodium
  • HY-125494
    Droxinavir hydrochloride

    SC-55389A

    		 HIV HIV Protease Infection
    Droxinavir hydrochloride (SC-55389A) is an HIV-1 protease inhibitor. Droxinavir hydrochloride binds to the S2 and S2' subsites of HIV-1 protease, and this interaction is regulated by protease amino acid residue 88, where the N88S mutation confers viral resistance. Droxinavir hydrochloride can be used in studies related to human immunodeficiency virus type 1 infection .
    Droxinavir hydrochloride
  • HY-105097
    Atevirdine mesylate

    U 87201E mesylate

    		 HIV Reverse Transcriptase Inflammation/Immunology
    Atevirdine (U 87201E) mesylate is a nonnucleoside reverse transcriptase (NNRT) inhibitor. Atevirdine mesylate can inhibit human immunodeficiency virus type 1 (HIV-1) with an IC50 of 0.06-1.6 μM. Atevirdine mesylate shows highly synergistic effects against Zidovudine/Didanosine-resistant clinical isolates of HIV-1 companied with Zidovudine (HY-17413)/Didanosine (Hy-B0249). Atevirdine mesylate can be used for the research of AIDS .
    Atevirdine mesylate
  • HY-P10429
    RCP168

    		CXCR Infection
    RCP168 is a highly selective and affinity CXCR4 receptor antagonist (IC50=5 nM). RCP168 has a stronger ability than natural chemical factors to inhibit the entry of HIV-1 (human immunodeficiency virus type 1) into host cells via CXCR4 receptors. RCP168 inhibits HIV-1 infection by blocking viral binding sites or inducing receptor internalization. RCP168 can be used to analyze the interaction between CXCR4 receptor and other chemical factor receptors .
    RCP168
  • HY-B0155B
    Vicriviroc malate

    SCH 417690 malate; SCH-D malate; MK-7690

    		 CCR HIV Infection Cancer
    Vicriviroc (SCH 417690) malate is an orally active CCR5 antagonist with the IC50 of 10 nM, and also inhibts MIP-1α and intracellular calcium release induced by the ligand RANTES (10 nM) with the IC50 values of 0.91 nM and 16 nM,,respectively. Vicriviroc malate can inhibits human immunodeficiency virus type 1 (HIV-1) infection, and can also used for study of cancer .
    Vicriviroc malate
  • HY-182678
    L-731988

    		HIV Integrase Infection
    L-731988 is an inhibitor targeting HIV-1 integrase. L-731988 inhibits HIV-1 replication by blocking integrase function. L-731988 exhibits ED50 values ranging from 0.5 μM to 3.14 μM against various HIV-1 isolates. L-731988 can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .
    L-731988
  • HY-182316
    P-1946

    		HIV Protease HIV Infection
    P-1946 is a HIV protease inhibitor with a human HIV-1 protease Ki of 2.600 nM. P-1946 has potent and selective in vitro antiviral activity and retains full antiviral activity against HIV isolates resistant to commercially available protease inhibitors. P-1946 can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .
    P-1946
  • HY-125494A
    Droxinavir

    SC-55389A free base

    		 HIV HIV Protease Infection
    Droxinavir (SC-55389A free base) is an HIV-1 protease inhibitor. Droxinavir binds to the S2 and S2' subsites of HIV-1 protease, and this interaction is regulated by protease amino acid residue 88, where the N88S mutation confers viral resistance. Droxinavir can be used in studies related to human immunodeficiency virus type 1 infection .
    Droxinavir
  • HY-126120
    BILA 1906 BS

    		HIV HIV Protease Infection
    BILA 1906 BS is a HIV protease inhibitor. BILA 1906 BS prevents HIV-1 replication via inhibition of viral protease-mediated cleavage of Gag and Gag-Pol polyprotein precursors during virion maturation. BILA 1906 BS blocks maturation of p24 proteins in wild-type HIV-1, impairing polyprotein processing and viral maturation. BILA 1906 BS can be used for the research of human immunodeficiency virus type 1 (HIV-1) infection .
    BILA 1906 BS
  • HY-111964S1
    Lenacapavir-d5

    GS-6207-d5

    		 Isotope-Labeled Compounds HIV Infection
    Lenacapavir-d5 (GS-6207-d5) is the deuterium labeled Lenacapavir (HY-111964). Lenacapavir (GS-6207) is an HIV-1 capsid inhibitor. Lenacapavir binds to the interface between capsid hexamers and CA monomers, disrupts capsid assembly and viral maturation, inhibits nuclear translocation of HIV-1 DNA, interferes with CA-mediated protein-protein interactions, reduces the formation of 2-LTR circles and pre-integration proviruses, induces aberrant capsids, and decreases the production of mature HIV-1. Lenacapavir exhibits activity against a variety of HIV-1 subtypes and clinical isolates. Lenacapavir is applicable to research related to human immunodeficiency virus type 1 (HIV-1) infection .
    Lenacapavir-d5

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: